The Library
Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMET) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma
Tools
Bailey, N. P., Stuart, N. S. A., Bessell, E. M., Child, J. A., Norfolk, D., Fletcher, J., Grieve, R. J., Simmons, A. V., Barnard, D. L., Jack, A., Farish, J., Dunn, Janet A., Woodroffe, C. M., Stack, C. and Cullen, M. H. (1998) Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMET) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Annals of Oncology, 9 (6). pp. 633-638. doi:10.1023/A:1008276700860 ISSN 0923-7534.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: https://doi.org/10.1023/A:1008276700860
Abstract
Background: Weekly alternating regimen known as CAPOMEt
is compared to standard cyclical chemotherapy (CHOP-Mtx)
in aggressive non-Hodgkin's lymphoma (NHL).
Patients and methods: Three hundred and eighty-one patients
with aggressive NHL were randomised to receive either cyclophosphamide,
doxorubicin, vincristine, prednisone and methotrexate
(CHOP-Mtx) on a cyclical basis or a weekly regimen
incorporating the same drugs with the addition of etoposide
(CAPOMEt).
Results: After pathological review, 281 patients were deemed
eligible. At the census date of 31 March 1994, 158 patients were
alive with a median follow up of 5.9 years (minimum 3.0 years).
Analysis of all patients and eligible patients showed no significant
treatment differences in the rates of complete remission
(CR), failure free survival (FFS) or overall survival (OS) between
the two arms. The actuarial median OS was 24 months
for CAPOMEt compared with 31 months for CHOP-Mtx,
with five-year actuarial survival rates of 37% and 43%, respectively.
Myelosuppression was significantly more severe with
CHOP-Mtx and neurotoxicity was much more common with
CAPOMEt.
Conclusion: Weekly CAPOMEt is equally effective as standard
cyclical CHOP-Mtx treatment in aggressive NHL.
Item Type: | Journal Article | ||||||
---|---|---|---|---|---|---|---|
Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) | ||||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Clinical Trials Unit Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||
Journal or Publication Title: | Annals of Oncology | ||||||
Publisher: | Oxford University Press | ||||||
ISSN: | 0923-7534 | ||||||
Official Date: | 1 June 1998 | ||||||
Dates: |
|
||||||
Volume: | 9 | ||||||
Number: | 6 | ||||||
Page Range: | pp. 633-638 | ||||||
DOI: | 10.1023/A:1008276700860 | ||||||
Status: | Peer Reviewed | ||||||
Publication Status: | Published | ||||||
Access rights to Published version: | Open Access (Creative Commons) |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |